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Clinical Relevance: The Sugen 5416/hypoxic rat model is a commonly used model 13 
of pulmonary hypertension. Sugen is a vascular endothelial growth factor (VEGF) 14 
inhibitor but to date the mechanism by which it actually facilitates the development of 15 
PH is unclear. Here we demonstrate that, at least in part, the mechanism involves 16 
activation of the aryl hydrocarbon receptor (AhR) and subsequent increased 17 
expression of CYP1A1 in the lung and translocation of AhR from cytoplasm to 18 
nucleus in human pulmonary artery smooth muscle cells (hPASMCs). This is 19 
accompanied by an increase in CYP1A1 and aromatase expression and an increase 20 
in estrogen synthesis. We show that sugen causes proliferation of blood outgrowth 21 
endothelial cells from PAH patients but only causes proliferation of hPASMCs when 22 
grown in hypoxic conditions. Sugen can also cause apoptosis in human 23 
microvascular pulmonary endothelial cells. Inhibition of AhR can reverse 24 
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sugen/hypoxic experimental PH and may be a novel approach to the treatment of 25 
PH. 26 
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Abstract 39 
Rationale: Rats dosed with the vascular endothelial growth factor (VEGF) inhibitor 40 
Sugen 5416 (Su), placed in hypoxia then restored to normoxia has become a widely 41 
used model of pulmonary arterial hypertension (PAH). The mechanism by which Su 42 
exaccerbates pulmonary hypertension is, however, unclear. Objectives: We 43 
investigated Su-activation of the aryl hydrocarbon receptor (AhR) in patient human 44 
pulmonary arterial smooth muscle cells (hPASMCs) and patient blood outgrowth 45 
endothelial cells (BOECs). We also examined the effect of AhR on aromatase and 46 
estrogen levels in the lung. Methods, Measurements and Main Results: Protein 47 
and mRNA analysis demonstrated that CYP1A1 was very highly induced in the lungs 48 
of Su/hypoxic (Su/Hx) rats. The AhR antagonist CH223191 (8mg/kg/day) reversed 49 
the development of PAH in this model in vivo and normalized lung CYP1A1 50 
expression. Increased lung aromatase and estrogen levels in Su/Hx rats were also 51 
normalized by CH223191 as was AhR nuclear translocator (ARNT [HIF-1β]) which is 52 
shared by HIF-1α and AhR. Su reduced HIF1α expression in hPASMCs. Su induced 53 
proliferation in BOECs and increased apoptosis in human pulmonary microvascular 54 
endothelial cells (hPMECs) and also induced translocation of AhR to the nucleus in 55 
hPASMCs. Under normoxic conditions, hPASMCs do not proliferate to Su. However 56 
when grown in hypoxia (1%) Su induced hPASMC proliferation. Conclusion: In 57 
combination with hypoxia, Su is proliferative in patient hPASMCs and patient BOECs 58 
and Su/Hx-induced PAH in rats may be facilitated by AhR-induced CYP1A1, ARNT 59 
and aromatase. Inhibition of the AhR receptor may be a novel approach to the 60 
treatment of pulmonary hypertension. 61 
249 words 62 
  63 
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Introduction  64 
Pulmonary arterial hypertension (PAH) is a progressive disease leading to right heart 65 
failure. This condition is defined by vascular remodelling and complex vascular 66 
lesion formation arising from accelerated proliferation in pulmonary endothelial, 67 
smooth muscle and fibroblast cells (1). Many vasoactive factors have been 68 
associated with the associated pathobiology including vascular endothelial growth 69 
factor (VEGF); however VEGF can exert both angiogenic and anti-angiogenic effects 70 
and its role in PAH is still unclear (2). Curiously, one administration of Sugen 5416 71 
(Su), a VEGFR inhibitor (with affinity at VEGFR2>VEGFR1) to rats combined with 72 
hypoxic exposure can cause severe experimental pulmonary hypertension (PH) that 73 
develops after a subsequent period of normoxia. This ‘Su/Hypoxic’ (Su/Hx) rat model 74 
develops high pulmonary pressures and, in some animals, occlusive/plexogenic-like 75 
pulmonary vascular lesions are also observed (3). The mechanism by which the 76 
combination of Su and hypoxia causes severe PH is still however, unclear but 77 
clarification of this would have important translational value in understanding clinical 78 
PAH.  79 
  Su has been studied as a potential therapy for advance malignancies. 80 
Curiously it has been observed that it has a long lasting inhibitory effect in animal 81 
tumor models despite it having a very short half-life of around 30 minutes; it is 82 
believed the long-lasting effects are due to it accumulating in cells (4, 5). Su is an 83 
agonist at the cytoplasmic aryl hydrocarbon receptor (AhR) which is cytoplasmic 84 
when unligated  (6). The AhR is a member of the basic helix–loop–helix/Per–ARNT–85 
Sim family of heterodimeric transcriptional regulators highly expressed in the lung (7) 86 
and influences the major stages of tumorigenesis as well as energy metabolism, lipid 87 
metabolism and diet-induced obesity (8, 9). We recently demonstrated that AhR 88 
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expression is elevated in human pulmonary artery smooth muscle cells (hPASMCs) 89 
from PAH patients and that AhR expression may be increased in small occluded 90 
pulmonary arteries from the Su/Hx rat model (10). PAH occurs up to four-fold more 91 
frequently in women (11) and dysfunctional estrogen synthesis and metabolism may 92 
play an important role in the pathobiology of pulmonary hypertension, both clinically 93 
and experimentally (10, 12-18). The AhR is a major regulator of the estrogen 94 
metabolising enzyme CYP1A1 and AhR can also regulate aromatase which is the 95 
major enzyme in estrogen synthesis (19). Therefore, the effects of Su on AhR 96 
activation in the pulmonary circulation of PAH patients is of interest.  97 
 To understand how hypoxia may synergise with the effects of Su on the AhR 98 
we investigated possible interactions between Su, AhR and hypoxia-inducible factor-99 
1α (HIF-1α) signaling.  This is of interest as the AhR nuclear translocator (ARNT/ 100 
HIF-1β) is a common binding partner for the AhR as well as HIF-1α and there is 101 
reciprocal crosstalk between hypoxia and AhR activation both in-vivo and in-vitro 102 
(20). In addition, HIF-1α has been implicated in the development of PAH (21). Under 103 
normoxic conditions, HIF-1α and HIF-2α are hydroxylated by prolyl hydroxylase 104 
(PHD) and complex with von Hippel-Lindau protein (VHL) causing subsequent 105 
proteasomal degradation. Under hypoxic conditions, PHD is inhibited and HIFα is 106 
stabilized and translocated to dimerize with HIF-1β in the nucleus. The heterodimer 107 
binds to the hypoxia response element (HRE) causing expression of target genes. 108 
Factor inhibiting HIF-1 (FIH-1) binds to HIF-1α and inhibits its transactivation function 109 
(22).  110 
 In light of these observations, we test the hypothesis that (at least in part) the 111 
effects of Su in experimental pulmonary hypertension may be due to activation of 112 
AhR and subsequent alterations in estrogen synthesis and CYP1A1 expression. We 113 
Page 5 of 51
5 
 
assess the interactions between Su, AhR and the HIF-1α pathway and translate our 114 
findings to clinically relevant cells from patients with PAH. 115 
 116 
Materials and Methods 117 
An expanded methods section is available in the online supplement. 118 
Animal studies 119 
See online supplement for ethical considerations and housing details.   120 
The rat model of Su/Hx is described in detail in the online supplement.  Briefly, adult 121 
female Wistar rats were given a single injection of Su 20mg/kg (s.c.) or 0.9% (s.c.) 122 
saline and exposed to hypoxia for 14 days then retained in normoxia for six weeks. 123 
CH223191 (8 mg/kg/day, Tocris, UK) was delivered to the animals in the final two 124 
weeks of the six weeks of normoxic exposure. 125 
Hemodynamics  126 
Heart rate, right ventricular systolic pressure (RVSP), systemic arterial pressure and 127 
cardiac output were measured and analyzed as previously described (10, 13). See 128 
online supplement for details. 129 
Right Ventricular Hypertrophy 130 
Right ventricular hypertrophy (RVH) was assessed by weight measurement of the 131 
right ventricular free wall and left ventricle plus septum. The ratio expressed as 132 
RV/(LV+S).  See online supplement for details.  133 
Lung Histopathology 134 
Pulmonary vascular remodelling was assessed as previously described (23, 24). 135 
5µm sagittal sections were obtained from left lungs. Sections were stained with 136 
Elastin/Picrosirius red and microscopically assessed in a blinded fashion. Pulmonary 137 
arteries (25 to 100 µm external diameter) were counted. The arteries were 138 
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considered muscularized if they possessed a distinct double-elastic lamina visible for 139 
at least half the diameter in the vessel cross-section. The percentage of vessels 140 
containing double-elastic lamina was calculated as number of muscularized 141 
vessels/total number of vessels counted×100.  142 
Human Pulmonary Arterial Cells and proliferation studies 143 
See online supplement for details. Briefly, distal hPASMCs derived from female 144 
patients with PAH and human blood outgrowth endothelial cells (BOECs) were 145 
prepared from female patients and characterized as previously described (25, 26). 146 
See online supplement Table 1 for PASMCs and BOECs patient details. Proliferation 147 
studies were carried out in charcoal-stripped media using manual cell counting and 148 
Countess II FL Automated Cell Counter (Thermo Fisher Scientific, UK) with 0.4% 149 
Trypan blue exclusion for assessment of viability. 150 
Human Pulmonary Arterial Cells and proliferation studies in hypoxia 151 
See online supplement for details. hPASMCs were maintained in charcoal-stripped 152 
media in hypoxic conditions for 48 hours in a hypoxia incubator chamber (1%; 153 
Bilrups Rothenburg, US). Proliferation studies were carried out using manual cell 154 
counting. 155 
AhR translocation studies  156 
The REAP method was applied to determine AhR protein translocation between the 157 
cytoplasm and nuclear fractions in hPASMCs and BOECs. See online supplement 158 
for details.  159 
Protein Analysis 160 
Protein expression in whole lung and hPASMCs was assessed by immunoblotting as 161 
described previously (13, 16) and in online supplement.  162 
qRT-PCR 163 
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mRNA expression was assessed in the lungs of rats and mice by qRT-PCR as 164 
described previously (13, 16) and in online supplement.  165 
  166 
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Estrogen Immunoassay 167 
The levels of E2 were determined by competitive immunoassay in lung samples and 168 
plasma from female rats from each group. See online supplement for details.  169 
Apoptosis 170 
Apoptosis assays were performed under normoxic conditions between passages 5 171 
and 8 in human pulmonary microvascular endothelial cells (PMECs) (Promocell, UK) 172 
from non-PAH donors. See online supplement for details. 173 
Results 174 
AhR and CYP1A1 expression in Su/Hx male and female rat lungs  175 
As discussed in the Introduction, we have previously shown that AhR expression is 176 
increased in human pulmonary artery smooth muscle cells (hPASMCs) from PAH 177 
patients and may be increased in small occluded arteries from Su/Hx rats (10). We 178 
therefore examined the protein and mRNA expression of AhR and CYP1A1 in the 179 
lungs from Su/Hx rats. As there is sexual dimorphism in PAH we compared male and 180 
female lungs to determine any sex differences in expression of AhR or CYP1A1. 181 
Figure 1 demonstrates that total AhR is equally expressed in the lungs of control and 182 
Su/Hx male and female rats at both protein and mRNA level (Figure 1A, B and E). 183 
CYP1A1 expression is the most sensitive marker of AhR activation and Figure 1C 184 
shows that, in Su/Hx male and female rat lungs, CYP1A1 mRNA expression is 185 
increased some 400-600 fold (largely due to the fact that CYP1A1 is not normally 186 
constitutively expressed (27)). This resulted in an increase in protein expression of 187 
CYP1A1 also (Figure 1D, E).  188 
To determine if AhR activation was specific to the Su/Hx model therefore, we 189 
investigated CYP1A1 expression in the lungs from models which were either not 190 
exposed to Su or did not require hypoxia to induce the pulmonary hypertensive 191 
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phenotype. We chose to examine hypoxic mice and the normoxic Smad1 knockout 192 
mouse model (28). In these models, lung CYP1A1 expression was actually reduced 193 
(Figure E1, A and B) suggesting Su is required for increased CYP1A1 and hypoxia 194 
alone does not increase CYP1A1. 195 
Effect of an AhR antagonist on the development of PH in the Su/Hx rat 196 
Having determined that CYP1A1 is expressed in the Su/Hx rat lung we wish to 197 
determine if inhibition of AhR in vivo would reverse established PH in this model. The 198 
AhR antagonist CH223191 reversed the increase in RVSP, RVH and pulmonary 199 
vascular remodelling in the Su/Hx rats (Figure 2 A-D). CH223191 had no effect on 200 
systemic arterial pressure, heart rate or cardiac output (Figure E2). LV weights did 201 
not change in the different treatment groups. 202 
Effect of an AhR antagonist on AhR, ARNT and CYP1A1 expression in the 203 
Su/Hx rat 204 
We confirmed that total AhR protein expression was not altered in whole lungs from 205 
Su/Hx rats and show that CH223191 had no effect on total AhR lung expression 206 
(Figure 3A, D). CH223191 reduced the increase in CYP1A1 expression observed in 207 
the Su/Hx rats (Figure 3B, D). ARNT expression was elevated in the Su/Hx rats and 208 
normalized by CH223191 (Figure 3C, D). We determined expression of AhR and 209 
CYP1A1 by immunohistochemistry to determine localization in the pulmonary 210 
arteries. CYP1A1 under normoxic conditions was expressed mainly in the 211 
endothelium and the adventitial layers. In the Su/Hx rats CYP1A1 expression was 212 
increased in line with the increase in vascular smooth muscle (Figure 3E). AhR 213 
expression was located in the medial layer and whilst total lung AhR expression did 214 
not increase in the Su/Hx rat, AhR staining was clearly evident in all the remodelled 215 
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vascular smooth muscle cells of small pulmonary arteries from the Su/Hx rats 216 
(Figure 3F).  217 
Effect of sugen on HIF1α 218 
We characterized the role of HIF-1α in hPASMCs. As a positive control, 219 
immunofluorescence demonstrated that 2 hour, but not 24 hour, stimulation with the 220 
PHD inhibitor CoCl2 caused a significant increase in the stabilisation of HIF-1α 221 
(Figure E3A-D). This was confirmed by immunoblotting in hPASMCs where HIF-1α 222 
was observed in both the cytoplasmic and nuclear compartments of the cell after 2 223 
hours treatment with CoCl2 (Figure E3E). Interestingly, Su treatment caused a 224 
significant reduction in both cytoplasmic and nuclear HIF-1α expression hPASMCs 225 
as measured by immunoflorescence (Figure E4A-C). This reduction in HIF-1α by Su 226 
was confirmed by immunoblotting (Figure E4D and E). Su had no effect on the 227 
protein expression of other regulatory components of the HIF-1α pathway such as 228 
PHD2, VHL or Factor inhibiting hypoxia inducible factor 1 (FIH1) (Figure E4F-I). 229 
Effect of an AhR antagonist on aromatase expression and estrogen in the 230 
Su/Hx rat lung 231 
We have previously shown that aromatase protein expression can be increased in 232 
the lungs from Su/Hx rats using the protocols used in this study (10). Here we show 233 
this was reversed following treatment with CH223191 (Figure 4A, B). We measured 234 
E2 levels in these lungs and found these to be elevated in the Su/Hx rat lung and 235 
normalized by CH223191 (Figure 4C). 236 
Effect of Su on the AhR/CYP1A1 axis in hPASMCs 237 
To examine the possibility that Su may activate AhR in hPASMCs we examined the 238 
effects of Su on AhR and CYP1A1 expression in hPASMCs. Neither 1 nor 5 µM Su 239 
affected total protein expression of AhR (Figure 5A, B). However, indicative of 240 
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activation of AhR, Su increased expression of CYP1A1 (Figure 5C, D). During 241 
activation, AhR is translocated into the nucleus, therefore total AhR expression may 242 
not change. We therefore investigated if Su (1 µM) could activate AhR and increase 243 
its translocation into the nucleus and demonstrated that by 90 minutes there was an 244 
increase in translocation of AhR from the cytoplasmic to nuclear fraction (Figure 5E).  245 
Effect of Su on hPASMC proliferation in normoxia and hypoxia 246 
We investigated the combined effects of hypoxia and Su in hPASMCs. Su on its own 247 
did not cause significant proliferation of hPASMCs (Figure 6A). When grown in a 248 
hypoxic environment however, Su caused significant hPASMC proliferation (Figure 249 
6B). We demonstrated that serum starvation caused apoptosis/reduction in cell 250 
number as did the positive control resveratrol (Figure 6C). Both Su (1 µM) and the 251 
AhR agonist FICZ (50 nM) also caused apoptosis as demonstrated by reduced cell 252 
number (Figure 6C). 253 
Effect of Su on BOECs 254 
We wished to investigate the effect of Su in BOECs derived from female PAH 255 
patients. Su (1µM) increased proliferation of BOECs (Figure 7A) and this was 256 
attenuated in the presence of AhR antagonist, CH223191 (Figure 7A). We 257 
demonstrated however, that both Su and CH223191 reduced BOEC viability 258 
assessed by trypan blue exclusion (Figure 7B). To examine the possibility that Su 259 
may activate AhR in BOECs, we examined the effects of Su (1µM) on AhR cytosolic 260 
to nuclear translocation in BOECs. We observed that after 60 minutes of stimulation 261 
with Su, there was a decrease in cytoplasmic AhR while nuclear AhR expression 262 
was unchanged (Figure 7C).  263 
 264 
Discussion 265 
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Here we demonstrate that the long-term effects of Su in experimental pulmonary 266 
hypertension may be due in part to its agonist effects on the AhR and subsequent 267 
alterations in estrogen synthesis and CYP1A1 expression. We translated our 268 
findings in cells from patients with PAH. Many compounds affect AhR activity 269 
including xenobiotics, drugs, flavonoids, indoles and tryptophan metabolites (7). 270 
Importantly the lung is exposed to many AhR activators in airborne particulate 271 
matter. Indeed, exposure to diesel exhaust can increase pulmonary vascular tone at 272 
high cardiac output (29). Functionally, AhR has been shown to play a critical role in 273 
vascular development, angiogenesis and cancer (30, 31). Unligated AhR is 274 
cytoplasmic, forming a complex with heat shock protein 90 (HSP90) and the co-275 
chaperones p23 and protein X-associated protein-2 (XAP2). Upon ligand binding 276 
phosphorylation of two protein kinase C sites leads to nuclear translocation of AhR. 277 
The AhR-chaperone complex dissociates and forms a heterodimer with ARNT (HIF-278 
1β) in the nucleus. ARNT binds both AhR and HIF-1α and is shared between the two 279 
signalling pathways (20).This heterodimer binds to dioxin-responsive element (DRE), 280 
leading to transcription of several genes, including CYP1A1 (7).  281 
 Metabolism of 17β-estradiol (E2) is mediated by several cytochrome P450 282 
enzymes (CYP) including CYP1A1 and CYP1B1. CYP1B1 expression in pulmonary 283 
arteries is elevated in experimental and clinical PAH and may influence the 284 
development of PAH (16). A single-nucleotide polymorphism (SNP) of CYP1B1 (and 285 
increased 16α-OHE1 in urine) has been associated with right ventricular (RV) 286 
function in female PAH patients and could underpin the sexual dimorphism in RV 287 
failure (17). Indeed, we and others have recently demonstrated that dysfunctional E2 288 
synthesis and metabolism may be involved in the increased prevalence of PAH in 289 
women (12, 13, 16, 28, 32-34). 290 
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Su is an inhibitor of both the VEGFR2 and VEGFR1 but has highest affinity at 291 
VEGFR2. It can induce lung cell apoptosis and emphysema (35). When combined 292 
with chronic hypoxia in rats, Su causes PH and right heart failure and, in some 293 
animals, it can induce obliterative vascular lesions (3). However, the mechanism by 294 
which the combined Su/Hx insult causes experimental PH is still unclear. It has been 295 
suggested that endogenous VEGFR inhibitors such as VEGF 165b, sVEGFR1 (s-296 
Flt1), Decorin, TNFSF15 and CXCL4 may influence the development of PAH (36).  297 
As Su is a ligand for AhR (6) we have investigated the hypothesis that 298 
activation of AhR may underpin Su/Hx experimental PH. As CYP1A1 gene 299 
expression is the most sensitive marker for AhR activation we firstly examined 300 
expression of AhR and CYP1A1 protein and mRNA in lungs removed from rats with 301 
PH induced by Su combined with hypoxia (3). The degree of experimental PH 302 
induced in this model reported in the literature is extremely variable. It can depend 303 
on the strain of rat, the sex of the rat, the protocol as well as the source of Sugen 304 
(37). Not all studies report obliterative vascular lesions in this model and in this study 305 
we saw too few of these to analyse. However, our degree of experimental PH in 306 
terms of RVSP, RVH and remodelling was commensurate with other studies using 307 
female rats (38). AhR was expressed at low levels in whole lungs of normoxic and 308 
Su/Hx male and female rats. It was expected that total AhR expression would not 309 
change as AhR activation normally follows translocation from the cytoplasm to the 310 
nucleus rather than an increase in expression. Activation of AhR was confirmed by 311 
the marked increase in CYP1A1 mRNA in lungs from the Su/Hx rats with a 600-fold 312 
increase in CYP1A1 being observed, due to the fact that CYP1A1 is not normally 313 
constitutively active and dependent on AhR for its activation (7). There were also 314 
increased levels of CYP1A1 protein in the lungs from the Su/Hx rats. To determine if 315 
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Su mediated the change in CYP1A1, we examined CYP1A1 mRNA expression in 316 
hypoxic rat lung and demonstrated that CYP1A1 expression was decreased when 317 
rats were exposed to hypoxia alone. This is consistent with the observation that 318 
hypoxia can inhibit AhR signalling and CYP1A1 expression in certain cell lines (39, 319 
40). This suggests that the increase in CYP1A1 in the Su/Hx rats was mediated by 320 
Su. To investigate this further and whether  AhR is a potential new target for the 321 
treatment of PAH, we examined the effects of the AhR antagonist CH223191 (41) in 322 
the Su/Hx rat. We chose to study female Su/Hx rats as we previously showed that (in 323 
female Wistar Kyoto rats) that AhR was increased in the lungs of female Su/Hx rats 324 
(10) and we have also demonstrated the importance of endogenous E2 to the 325 
development of PH in the female Su/Hx rat (13). We adopted CH223191 as a 326 
selective and potent AhR inhibitor with no reported off-target effects that would 327 
influence our results (42, 43). The results demonstrated that RVSP, RVH and 328 
pulmonary vascular remodelling were all markedly increased in the Su/Hx rats. 329 
There was no effect of CH223191 on systemic pressures, heart rate or cardiac 330 
output. The experimental PH was accompanied by increase expression of CYP1A1 331 
and ARNT which was normalized by the AhR antagonist. These results suggest that 332 
Su/Hx-induced PH is associated with AhR activation of CYP1A1 as well as increased 333 
expression of ARNT/HIF-1β, providing a mechanism of cross-talk between the AhR 334 
and hypoxia. Su decreased HIF-1α expression in hPASMCs whilst having no effect 335 
on nuclear translocation of HIF-1α or affecting other aspects of HIF-1α signalling. 336 
Whilst increased HIF-1α has been observed in lungs from patients with PAH (21), 337 
others have also reported a decreased expression of HIF-1α in hPASMCs from 338 
patients and suggested this may underlie increased pulmonary vascular contraction 339 
(44). 340 
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 By immunohistochemistry we determined that CYP1A1 was mainly 341 
expressed in the endothelium in the normoxic rat pulmonary arteries. This is 342 
consistent with the endothelium being the first line of defence, via the AhR, between 343 
the arteries and circulating vasoactive/harmful substances. However CYP1A1 344 
expression was also observed in the medial layer of small pulmonary arteries from 345 
the Su/Hx rats, suggesting an effect of Su on CYP1A1 expression in PASMCs from 346 
these rats.  347 
 Aromatase (CYP19A1) is a member of the cytochrome P450 superfamily and 348 
synthesizes E2 through the aromatization of androgens, specifically testosterone and 349 
androstenedione. We have recently demonstrated that pulmonary artery smooth 350 
muscle cells express aromatase and that aromatase expression is increased in 351 
pulmonary arteries from PAH patients (13). We have shown previously that inhibition 352 
of aromatase with anastrozole has a therapeutic effect in animal models of PH 353 
(including the Su/Hx rat) (13). In addition, anastrozole has been shown to be 354 
clinically effective in PAH (12). It has previously been shown that AhR can induce the 355 
CYP19 (aromatase) gene (19). We confirmed that aromatase protein expression was 356 
increased in the lungs from Su/Hx rats and that this was normalized by the AhR 357 
antagonist. Consistent with this we also observed an increase in E2 in the lungs from 358 
the Su/Hx rats which was also normalized by the AhR antagonist. Interestingly the 359 
increase in lung E2 appears to be variable between species and studies; as in a 360 
previous study where we induced PH in Wistar Kyoto rats, there was no increase in 361 
lung E2 despite increased aromatase expression (10). It is possible that given 362 
different experimental animals at different times of year there is variability in the 363 
metabolism of E2 in the lung which introduces variability in absolute E2 levels which 364 
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we need to consider as a potential limitation in the interpretation of these studies in 365 
animal models.  366 
These studies support the hypothesis that Su can regulate AhR and CYP1A1 367 
in the lung and this contributes to experimental PH. To examine if this translates into 368 
humans, we examined the effect of Su in hPASMCs derived from females with PAH 369 
as well as human pulmonary endothelial cells and female PAH-derived BOECs. Su 370 
had no effect on total AhR expression in hPASMCs. However, this might not be 371 
expected as AhR is activated by translocation from the cytoplasm to the nucleus. We 372 
therefore examined the effect of Su on AhR protein levels in the cytoplasm and the 373 
nucleus and showed that Su did cause an increase in nuclear AhR expression in 374 
hPASMCs. However, in BOECs, the cytoplasmic AhR expression decreased whilst 375 
the nuclear expression remained constant. Regulation of subcellular AhR localization 376 
is complex and dynamic involving mechanisms for retention and stabilization of AhR 377 
in the cytosol via XAP2 and continuous nuclear export. Also, binding of ligand can 378 
increase the rate of nuclear AhR import without stopping nuclear AhR export (45). 379 
Consistent with this activation of AhR, Su increased CYP1A1 protein expression in 380 
the hPASMCs. E2 can be converted 2-hydroxyestradiol (2-OHE2) by CYP1A1/2, 381 
CYP1B1 and CYP3A4. CYP1A1 also metabolizes estrone (E1) and E2 to 2-OHE2 382 
and 16α-hydroxyestrone (16α-OHE1); these metabolites are mitogenic in hPASMCs 383 
and may contribute to the development of PAH (16, 46). Unfortunately, at this time 384 
we are still developing accurate methods for measuring low concentrations of E2 385 
metabolites from cells so we were unable to measure these directly. The effects of 386 
AhR on E2 synthesis and metabolism are of interest as major PAH registries report a 387 
greater incidence of PAH among women than men (47) and E2 metabolism is 388 
implicated in the increased penetrance of heritable PAH (HPAH) among female 389 
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patients harbouring a mutation in the gene encoding bone morphogenetic protein 390 
receptor-II (BMPRII) (18). 391 
Su requires a ‘second hit’ of hypoxia followed by a period of normoxia to induce 392 
experimental PH although this can be strain dependent (37). We assessed whether 393 
hypoxia could influence the effect of Su in hPASMCs by determining proliferation 394 
whilst culturing cells in either normoxia or hypoxia. We show that Su did not induce 395 
proliferation in normoxic cells but did in hypoxic cells. This demonstrates synergy 396 
between Su and hypoxia in hPASMCs. Given that ARNT protein levels are 397 
normalized by the AhR antagonist, it is possible that hypoxia synergizes with AhR 398 
activation via ARNT.  399 
It is thought that endothelial cell apoptosis may initiate vascular remodelling in 400 
experimental PAH. This could cause degeneration of pre-capillary arterioles or select 401 
apoptosis-resistant ECs that contribute to "angioproliferative" plexiform lesions (48). 402 
As Su can induce apoptosis we studied this in human pulmonary endothelial cells 403 
and showed that both Su and an AhR agonist could induce apoptosis in these cells. 404 
Apoptosis is providing a further potential role for the AhR in pulmonary vascular 405 
remodelling. Endothelial cells are more subject to contact inhibition in intact arteries 406 
than hPASMCs and do not normally proliferate. However it has been shown that 407 
BOECs from patients with PAH can exhibit increased proliferation (49). Indeed, it is 408 
considered that there is a key role for dysregulated endothelial proliferation in the 409 
development of clinical PAH (50). We demonstrate that Su can induce proliferation of 410 
BOECs from patients which could perhaps precede and contribute to the ability of Su 411 
to increase the development of occlusive lesions in some animals. The slight 412 
decrease in cell viability caused by Su is likely to be a consequence of contact 413 
inhibition occurring in these cultures.  414 
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In summary, our data provides new insight into potential mechanisms behind the 415 
Su/Hx model. The results suggest that Su may activate AhR nuclear translocation 416 
and subsequent activation of CYP1A1, apoptosis and aromatase expression. The 417 
resulting increase in E2 synthesis and metabolism, and apoptosis may contribute to 418 
experimental PH. We also demonstrate directly that Su and hypoxia synergize, 419 
perhaps via ARNT, to cause hPASMC proliferation. Our study also suggests that 420 
inhibition of AhR may be a potential novel approach to the treatment of PAH should 421 
these results translate to the human situation. This is summarized in Figure 7.  422 
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Figure legends 612 
Figure 1. The expression of AhR and CYP1A1 in lung tissue of Sugen/Hypoxic 613 
(Su/Hx) animal model. The expression of AhR mRNA (A) and protein (B) and 614 
expression of CYP1A1 mRNA (C) and protein (D) in whole lung from male and 615 
female Su/Hx rats and their normoxic litter-mates (n =3–4 per group, repeated in 616 
triplicate). Representative immunoblots of AhR and CYP1A1 protein expression in 617 
whole lung from male and female Su/Hx rats and their normoxic litter-mates (E). 618 
Vertical lines have been added to clarify experimental groups. Data displayed as 619 
mean ± SEM. ***P < 0.001, ****P < 0.0001 determined by one-way ANOVA with 620 
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Tukey’s post-hoc test. AhR = Aryl hydrocarbon receptor; CYP1A1=Cytochrome P450 621 
enzyme 1A1; CYP1B1=Cytochrome P450 enzyme 1B1; RQ = relative quantity. 622 
 623 
Figure 2. Effect of the AhR antagonist CH223191 on Sugen/Hypoxic (Su/Hx) 624 
pulmonary hypertension in female rats. (A) Right ventricular systolic pressure 625 
(RVSP, n=5-6 per group), (B) Right ventricular hypertrophy (RVH, n=8 per group) 626 
and (C) percentage of remodelled arteries in lungs without treatment (control), with 627 
CH223191 alone, Su/Hx treatment with vehicle or CH223191, n=5-6. (D) 628 
Representative images showing elastic laminae stained with Elastin/picrosirius red. 629 
Scale bar represents 20µm. Data represents mean ±SEM. * P<0.05, **P<0.01 630 
***P<0.001 as indicated, determined by one way ANOVA followed by Bonferroni 631 
post-hoc test. 632 
 633 
Figure 3. Effect of the AhR antagonist CH223191 on protein expression of AhR, 634 
CYP1A1 and ARNT in female rat lung. AhR expression (n=4) (A), CYP1A1 635 
expression (B) ARNT (C) expression with representative immunoblots (n=4-6) (D).  636 
C=Control, CH=CH223191, Su/Hx=Sugen/hypoxic rats, Su/Hx +CH= sugen/hypoxic 637 
rats treated with CH223191. Representative CYP1A1 immunostaining in pulmonary 638 
arteries from rats. Scale bar: 50µm. (E) Representative AhR immunostaining in 639 
pulmonary arteries from rats. Scale bar: 50µm (F). Data is shown as mean ±SEM. * 640 
P<0.05, as indicated, determined one way ANOVA followed by Bonferroni post-hoc 641 
test.  642 
 643 
Figure 4. Effect of an AhR antagonist on aromatase expression and estrogen in the 644 
Su/Hx rat lung. Aromatase expression in female rat lung, (n=3) (A) and 645 
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representative immunoblot (B). Local estrogen levels within rat female lung (n=4-5). 646 
(C)  C=Control, CH=CH223191, Su/Hx=Sugen/hypoxic rats, Su/Hx +CH= 647 
sugen/hypoxic rats treated with CH223191. Data is shown as mean ±SEM. * P<0.05 648 
as indicated, determined one way ANOVA followed by Bonferroni post-hoc test. 649 
 650 
Figure 5. Effect of Sugen on AhR and CYP1A1 expression in hPASMCs.  AhR (A,B) 651 
and CYP1A1 (C,D) protein levels in PASMCs from female patients with PAH 652 
stimulated with 1 and 5µM SU5416 for 24 hours (n=3-4 different cell lines). 653 
Representative western blots (B,D) have had irrelevant lanes removed on the right 654 
hand side. Sugen caused nuclear translocation of aryl hydrocarbon receptor (AhR) 655 
after 30, 60 and 90 minutes (E) (n = 3 for all groups, * P<0.05 as indicated, 656 
determined by area under the curve). AhR protein expression was normalized to α-657 
tubulin and nucleoporin as markers for cytosolic and nuclear enrichment, 658 
respectively. Data is displayed as a mean ±SEM. * P<0.05 as indicated, determined 659 
by one way ANOVA followed by Bonferroni post-hoc test. 660 
 661 
Figure 6. Sugen stimulates proliferation of female PAH patient PASMCs under 662 
hypoxia, but not under normoxia. Stimulation with Sugen had no effect on 663 
proliferation in female hPASMCs in normoxia (A), however, in hypoxia 1 µM Sugen 664 
5416 induced cell proliferation (B), n=4, repeated 3 times. Stimulation with 1 µM 665 
Sugen 5416 and aryl hydrocarbon receptor (AhR) agonist FICZ induced a decrease 666 
in cell number of female pulmonary microvascular endothelial cells (C). 100 µM 667 
Resveratrol was used as positive control, while endothelial cell growth media served 668 
as negative control for apoptosis, n=4, repeated 3 times. Data is displayed as mean 669 
±SEM. * P<0.05, **P<0.01 ***P<0.001 as indicated, determined one way ANOVA 670 
Page 29 of 51
29 
 
followed by Bonferroni post-hoc test. FICZ=5,11-Dihydro-indolo[3,2-b]carbazole-6-671 
carboxaldehyde, 6-Formylindolo[3,2-b]carbazole. 672 
 673 
Figure 7. Sugen stimulates proliferation of BOECs from female patients with PAH. 674 
Stimulation with Sugen increased proliferation in female PAH-derived BOECs (A), 675 
however, both aryl hydrocarbon receptor (AhR) antagonist 1 µM CH223191, and 1 676 
µM Sugen 5416 reduced cell viability in BOECs by trypan blue exclusion (B), n=3, 677 
repeated 3 times. Data is displayed as mean ±SEM. * P<0.05, **P<0.01 as indicated, 678 
determined by one way ANOVA followed by Bonferroni post-hoc test. Sugen caused 679 
nuclear translocation of AhR after 60 minutes (C) AhR protein expression was 680 
normalized to α-tubulin and nucleoporin as markers for cytosolic and nuclear 681 
enrichment, respectively. Data is displayed as a mean ±SEM. * P<0.05 as indicated, 682 
determined by area under the curve.  (D) Our data suggest that Su may activate AhR 683 
nuclear translocation and subsequent activation of CYP1A1, apoptosis and 684 
aromatase expression. The resulting increase in E2 synthesis and metabolism may 685 
contribute to the experimental PH. We also demonstrate directly that Su and hypoxia 686 
synergize, perhaps via ARNT, to cause hPASMC proliferation; suggesting inhibition 687 
of AhR may be a potential new approach to the treatment of PAH. AhR, Aryl 688 
Hydrocarbon Receptor; ARNT (HIF1β), Aryl Hydrocarbon Receptor Nuclear 689 
Translocator; CYP1A1=Cytochrome P450 1A1; EC, Endothelial Cell; PAH, 690 
Pulmonary Arterial Hypertension; PASMCs, Pulmonary Arterial Smooth Muscle Cell. 691 
 692 
 693 
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Supplement text 
Methods 
Animal studies 
Ethical information 
All experimental procedures were carried out in accordance with the United Kingdom 
Animal Procedures Act (1986) and with the "Guide for the Care and Use of 
Laboratory Animals" published by the US National Institutes of Health (NIH 
publication No. 85-23, revised 1996), and ethical approval was also granted by the 
University of Glasgow Ethics Committee. Experimental procedures using hPASMCs 
conform to the principles outlined in the Declaration of Helsinki. Experimental 
procedures using human pulmonary artery smooth muscle cells conform to the 
principles outlined in the Declaration of Helsinki. All non-PAH human lung biopsies 
were confirmed as macroscopically normal and collected from lung cancer patients 
undergoing pneumonectomy with no reported presence of PAH. 
Housing details 
Rodents were housed in a 12-hour light dark cycle with access to food and water ad 
libitum. Wistar female rats, aged 9 weeks, were purchased from Harlan, UK. The 
animals were housed in a 12-hour light-dark cycle with access to food and water ad 
libitum. Animals were housed together to promote synchronisation of their estrous 
cycles. In order to ensure animals were synchronising together, a blunt, shortened 
tip of a Pasteur pipette was placed at the vaginal orifice. One drop of PBS was gently 
expelled into the vagina and aspirated back before being transferred to a microscope 
slide. Smears were examined microscopically and classified as to the stage of the 
cycle.  
In vivo Hemodynamic Measurements 
Animals were anaesthetically induced in 3% (v/v) isoflurane and then maintained at 
1.5-2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. Right 
ventricular systolic pressure (RVSP) measurements were taken using a Polyimide 
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Mikro-Tip pressure volume catheter (ADI instruments SPR-869NR); 12.5cm effective 
length, with four electrodes and a pressure sensor centered between E2 and E3. 
The catheter was used as per the manufacturer’s instructions and attached to 
corresponding software (LabChart Pro). This catheter was inserted into the jugular 
vein and guided into the right ventricle of the heart to measure RVSP. After RVSP 
was determined, the carotid artery was isolated and the same catheter used to 
determine mean systemic arterial pressures. This pressure- volume (PV) loop 
system also generated the cardiac output (CO) data. Blood was collected 
immediately in a heparinised syringe for plasma analysis.  
Right ventricular hypertrophy and tissue harvest 
Immediately following hemodynamic assessment, the heart and lungs were flushed 
with ice-cold PBS at a low pressure to clear peripheral blood cells. The right lung 
was excised for molecular analysis. The left lung was inflated with 10% (v/v) neutral 
buffered formalin (NBF) and left in NBF solution for 48 hours before paraffin 
processing and embedding for immunohistological analysis. Right ventricular 
hypertrophy (RVH) was assessed by the Fulton Index (dry weight of the right 
ventricle/ (dry weight of the left ventricle + septum). Animals assigned to hypoxic 
conditions were placed in a hypobaric chamber (atmospheric pressure 550 mbar) for 
two weeks and then placed in normal room pressure (1013 mbar) for a further six 
weeks. CH223191 (8mg/kg/day, Tocris, UK) dosing was administered to the animals 
by oral gavage in the final two weeks of being at room pressure (reversal study). 
Charcoal-Stripped Fetal Bovine Serum  
Fetal bovine serum (FBS; Sera Labs, UK) was charcoal-stripped twice to remove 
estrogens. Dextran-coated charcoal (1% (w/v), Sigma-Aldrich, UK) in FBS was 
agitated gently overnight at 4ºC. Samples were centrifuged at 1811 g at 4ºC for 30 
minutes. The stripped serum was decanted and filtered through a 0.22µm filter. 
Human pulmonary arterial cells and proliferation studies 
Human PAH patient PASMCs and BOECs were provided by Professor Nicholas W. 
Morrell (University of Cambridge). We chose to study cells from female patients as 
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these were most readily available and reproducible, since most PAH patients are 
female. Female BOECs were cultured from the peripheral blood of three PAH 
patients according to previous studies (1). BOECs were used between passages 4 
and 5. Patient characteristics are shown in Table 1. Female hPASMCs were 
explanted from the distal pulmonary microvasculature from subjects with PAH. 
Assays were performed between passages 5 and 8. Cells were seeded in 24-well 
plates (for cell proliferation) and 6 well plates (for protein, RNA or analysis) at a 
density of 10,000 cells per cm2. Cells were grown to 50-60% confluency and then 
synchronized by serum-deprivation (0.2% (v/v) charcoal-stripped FBS) in phenol-red 
free DMEM (Invitrogen, UK) for 24 hours for all experiments. Proliferation studies 
were carried out in charcoal-stripped media using either manual cell counting or 
Countess II FL Automated Cell Counter (Thermo Fisher Scientific, UK) with 0.4% 
Trypan blue exclusion for assessment of viability. 
Human pulmonary arterial cells and proliferation studies in hypoxia 
Female hPASMCs (as above) between passages 5 and 8 were used to assess the 
effects of Sugen on proliferation in hypoxic conditions. Cells were seeded in 24-well 
plates at a density of 10,000 cells per cm2. Cells were grown to 50-60% confluency 
and then synchronized by serum-deprivation (0.2% (v/v) charcoal-stripped FBS) in 
phenol-red free DMEM (Invitrogen, UK) for 24 hours for all experiments. Cells were 
maintained in charcoal-stripped media in hypoxic conditions (1% O2, 5% CO2) for 48 
hours in hypoxia incubator chamber (Bilrups Rothenburg, US). Proliferation studies 
were carried out using either manual cell counting or Countess II FL Automated Cell 
Counter (Thermo Fisher Scientific, UK) with 0.4% Trypan blue exclusion for 
assessment of viability. 
AhR translocation in hPASMCs  
The REAP method was applied to determine AhR protein translocation between the 
cytoplasm and nuclear fractions in PAH patient hPASMCs and BOECs (2). Cells 
were grown in monolayer in 10 cm dishes, washed with ice cold PBS, collected in 
PBS, and centrifuged for 10 seconds at 10,000 rpm. Then the supernatant was 
removed, and the pellet was re-suspended in 900 µl of 0.1% (v/v) NP-40 (Abcam 
ab142227), triturated and 300 µl removed as whole cell lysate and added to 100 µl of 
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4x NUPAGE sample buffer. Remaining material (600 µl) was centrifuged as before, 
and 330 µl of supernatant was removed as the cytosolic fraction and added to 100 µl 
of 4x NU sample buffer (ThermoFisher Scientific, UK). The remaining supernatant 
was removed and pellet re-suspended in 1 ml of 0.1% NP-40 (in PBS, Sigma, UK) 
and centrifuged. The supernatant was discarded and the pellet re-suspended in 90 µl 
of NUPAGE sample buffer as the nuclear fraction. Nuclear and cytoplasmic fractions 
were confirmed by western blotting for nucleoporin/lamin A and alpha tubulin 
respectively 
Protein Analysis 
Protein expression was assessed by immunoblotting in whole lung and hPASMCs. 
Whole lung rat samples were homogenized and hPASMCs were lysed in ice-cold 1% 
(v/v) lauryl maltoside (Abcam, UK) solution in PBS. Protein concentrations were 
determined by nanodrop (ND-1000 spectrophotometer (Thermo Scientific, UK). 20µg 
of protein was loaded for hPASMCs and whole lung homogenates, for protein 
identification by SDS-PAGE and immunoblotting. Protein expression was assessed 
using the following antibodies: anti-AhR (ab84833 1:500), anti-CYP1A1 (Abcam 
ab79819 1:1000), anti-ARNT (Cell signalling 3361 1:1000), anti-aromatase (Abbexa, 
abx13974 1:200), anti-HIF-1α (BD, 610958) anti-PHD2 (Cell Signaling #4835 
1:1000), anti-VHL (Cell Signaling #2738 1:1000) and FIH1 (Novus NB100-428 1:500) 
by overnight incubation at 4°C. Membranes were then incubated with appropriate 
HRP-conjugated secondary antibodies. Immunoblots were developed using Pierce™ 
ECL Western Blotting Substrate (Life Technologies) or EMD Millipore Immobilon™ 
Western Chemiluminescent HRP Substrate (ECL) (Fisher Scientific), and normalized 
to either GAPDH (Abcam UK, ab8264; 0.2µg/ml) or beta actin (Sigma, A5441). 
Densitometrical analysis was performed using TotalLab TL100 software.  
Immunoflorescence 
Cellular localization of HIF-1α in hPASMCs was assessed by immunoflorescence. 
Briefly, cells were grown on glass coverslips until 50-60% confluent. Stimulated cells 
were then washed in PBS and fixed in 4% paraformaldehyde (PFA) for 15 minutes at 
room temperature. Cells were then permeabilized with 0.2% Triton X-100/PBS 
(Sigma, UK) and blocked with 2%BSA/PBS with 0.05% Tween-20 (Sigma, UK). HIF-
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1α primary antibody (1:250, Novus Biologicals, NB100-134) was added to the 
coverslips and incubated overnight at 4ºC. Cells were then washed in PBS and 
incubated with secondary antibody for 1 hour at room temperature (Alexa goat anti-
mouse 488, ThermoFisher Scientific, UK). After a further PBS wash, ProLong™ 
Diamond antifade mountant with DAPI (ThermoFisher Scientific, UK) was applied to 
the coverslips and mounted on glass slides for imaging. Images were acquired using 
an LSM-510 laser-scanning confocal microscope (Zeiss, Germany). Images were 
then analysed using ImageJ and mean pixel intensity was used to determine relative 
florescence within each cell relative to cellular area. 
qRT-PCR 
Total RNA was extracted using miRNeasy mini kit (Qiagen, Germany) according to 
the manufacturer’s instructions. RNA concentration was determined using Nanodrop 
1000 spectrophotometer (Thermo Scientific). Expression of mRNA of CYP1A1 
(Rn00487218_m1, Mm00487218_m1) and AhR (Rn00565750_m1) was assessed 
by Taqman qRT-PCR. To obtain a fold change mRNA expression data was 
normalised to β2 microglobulin (Rn00560865_m1, Mm00437762_m1). 
Lung immunolocalization  
Additional sections were stained using anti-AhR (Abcam ab153744 1:200), anti-
CYP1A1 (Abcam, ab79819 1:100) antibodies. An anti-rabbit IgG secondary antibody 
was used for each primary antibody (Vector Laboratories ImmPress kit) and protein 
immuno-localization was visualized with the DAB substrate kit (Vector labs UK (sk-
4600) for CYP1A1 and Vector Red substrate kit (sk-5100). 
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Estrogen Immunoassay 
The levels of 17β-estradiol were determined by competitive immunoassay in lung 
samples from female rats from each group. 20µg of protein was loaded and assayed 
in duplicate as per the manufacturer’s instructions (Demeditec, USA). The plate was 
read at a wavelength of 405nm for kinetic and end point measurements (SpectraMax 
M2 plate reader, Molecular Devices, California, USA).  
Apoptosis 
Apoptosis assays were performed between passages 5 and 8 in pulmonary 
microvascular endothelial cells (PMECs) (Promocell, UK). Cells were grown to ~90% 
confluence and then synchronized by serum-deprivation in serum-free basal phenol-
red MV endothelial cell media (Promocell, UK) for 2 hours for all experiments. Cells 
were then stimulated with Sugen (Novartis, UK), 50 nM 5,11-Dihydroindolo[3,2-
b]carbazole-6-carboxaldehyde (FICZ, Sigma, UK) and 100 µM Resveratrol (Sigma, 
UK), which served as positive control for apoptosis, for 24 hours in 2% charcoal-
stripped basal EC media. Changes in cell number were assessed with Countess II 
FL Automated Cell Counter (ThermoFisher Scientific, UK).  
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Figure E1 
CYP1A1 expression in the lungs of female and male hypoxic mice compared with 
their normoxic controls. n=4-5 (A). CYP1A1 expression in the lungs of female and 
male mice heterogeneous for the Smad1 gene (Smad1+/-) compared with their 
wildtype (WT) controls. n=4-6. Data displayed as mean ± SEM. *P < 0.05, **P < 0.01 
determined by one-way ANOVA with Tukey’s post-hoc test. CYP1A1=Cytochrome 
P450 enzyme 1A1; RQ = relative quantity; F=female; M=male; WT=wildtype. 
 
Figure E2 
Mean Systemic Arterial Pressure (mSAP), cardiac output and heart rate in female 
rats exposed to CH223191, with and without Su/Hx. mSAP (A), heart rate (B), 
cardiac output (C). Data was analysed by one way ANOVA followed by Bonferroni 
post test, n=6-8. Su/Hx=sugen/hypoxic. 
Figure E3  
HIF-1α protein (green) localization in the cytoplasm and nuclei of hPASMCs before 
and after treatment with 200 µM CoCl2 at 2 hour and 24 hour time points (A–D). 
Nuclei were counterstained with DAPI (blue). Scale bar=50 µm. Relative HIF-1α 
protein expression in cytoplasmic vs nuclear after addition of 200 µM CoCl2 (E). 
Lamin-A and GAPDH were used as loading controls for nuclear and cytoplasmic 
compartments, respectively. n=3-4 biological replicates. Data is displayed 
mean ± SEM. *P < 0.05, determined by one-way ANOVA with Tukey’s post-hoc  test. 
Figure E4  
HIF-1α protein (green) localization in the cytoplasm and nuclei of hPASMCs before 
and after treatment with Sugen 5416 (5 µM) for 24 hours  Nuclei were counterstained 
with DAPI (blue). Scale bar=50µm (A-C). Cytoplasmic and nuclear levels of HIF-1α 
protein before and after 24 hour treatment with Sugen 5416 (5 µM). Lamin-A and 
GAPDH were used as loading controls for nuclear and cytoplasmic compartments, 
respectively (D) and representative immunoblots (E). Whole cell protein levels of 
VHL (F), PHD2 (G), FIH1 (H) and representative immunoblots (I). n=3-4 biological 
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replicates. Data is displayed mean ± SEM. *P < 0.05, **P<0.01, ***P<0.001 
determined by one-way ANOVA with Tukey’s post-hoc  test. 
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Figure E1 
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Figure E2 
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Figure E3 
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Figure E4 
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Table 1 Age (where known) and disease status of patients (all female) from whom 
cells were derived. 
 
Cell type Cell line Age Disease status 
Female 
hPASMC 
35MP 41 BMPRII mutant (N903S) 
 37MP 24 IPAH 
 38MP  IPAH 
 73MP 30 BMPRII mutant (R899X) 
 113MP 45 IPAH 
 115MP 53 Associated PAH (Congenital 
Heart Disease) 
Female 
BOEC 
PAH9 62 IPAH 
 PAH15 24 IPAH 
 B4 37 BMPRII mutant (W9X) 
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Figure 2 
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Figure 6 
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Figure 7 
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